Toosendanin (0.5 and 1 mg/kg, Intraperitoneal injection daily for 7 days) alleviates DSS-induced experimental colitis by inhibiting M1 macrophage polarization and regulating NLRP3 inflammasome and Nrf2/HO-1 signaling, and may provide a novel Chinese patent medicine for the treatment of murine colitis.
| Animal Model: | Forty-eight male C57BL/6 mice weighing 20-22 g. |
| Dosage: | 0.5 and 1 mg/kg. |
| Administration: | Intraperitoneal injection daily for 7 days. |
| Result: |
Protected against DSS-induced colitis in mice.
Inhibited the expression of proinflammatory cytokines in DSS-induced UC and improved oxidative stress. |